FDA Says It Will Review Affymax Drug

7/27/11Follow @xconomy

Palo Alto, CA-based Affymax (NASDAQ: AFFY) and its partner, Japan-based Takeda Pharmaceuticals, said today that the FDA has agreed to review their application to market a new anemia drug in the U.S. If the FDA agrees to clear peginesitide (formerly known as Hematide) for sale in the U.S., it would be the first once-monthly anemia drug for patients with kidney dialysis, and would compete with products from Amgen.

By posting a comment, you agree to our terms and conditions.